Position of the Transparency Council – Ospolot (sultiam)
At its meeting on 22 August 2022 the Transparency Council adopted Position No. 81/2022 on the legitimacy of granting consent for reimbursement of the medicinal product Ospolot (sulthiame) for the indications: epilepsy, drug-resistant epilepsy, drug-resistant epilepsy in the course of Rett syndrome.